logo-loader
RNS
Imaging Biometrics Ltd

Imaging Biometrics - Publication of Phase 1 Clinical Trial

RNS Number : 4746H
Imaging Biometrics Limited
09 June 2026
 

Imaging Biometrics Limited

("Company")

9 June 2026

 

Publication of Phase 1 Clinical Trial of Oral Gallium Maltolate (GaM) in Recurrent Glioblastoma and Reopening of Expanded Access Programme

Imaging Biometrics Limited (LSE: IBAI) announces the publication in the peer-reviewed journal Neuro-Oncology Advances describing the results from the Phase 1 clinical trial (NCT04319276) of oral gallium maltolate in patients with recurrent or treatment-refractory glioblastoma (GBM). Imaging Biometrics, LLC, a wholly owned subsidiary of Imaging Biometrics Limited, was the primary sponsor of the trial. This marks the first in-human study results of GaM for glioblastoma. The trial, conducted at the Froedtert and Medical College of Wisconsin Clinical Cancer Center, demonstrated that oral GaM was well tolerated and showed preliminary signals of survival benefit, supporting further clinical development.

Summary of published results

The trial was a dose-escalation study designed primarily to assess safety and to establish a recommended Phase 2 dose (RP2D). Key findings reported by the investigators were:

•     Oral gallium maltolate was safe and well tolerated at all dose levels up to 2,500 mg/day. Only Grade 1 or Grade 2 adverse effects were observed, with no Grade 3 or higher toxicities. No kidney toxicity was seen. The absence of nephrotoxicity is particularly notable given historical renal risks associated with earlier gallium formulations and supports the feasibility of chronic oral administration in patients with recurrent glioblastoma.

•     The recommended Phase 2 dose (RP2D) was determined to be 2,000 mg/day.

•     Among the 22 patients evaluable for tumour response, the investigators reported a median overall survival of 16 months and a median progression-free survival of 2.5 months. The authors note that the median overall survival compares favourably with the range of 5.5 to 12.6 months reported in a published meta-analysis of treatments for recurrent GBM, while emphasising that no conclusions on efficacy can be drawn from a Phase 1 study of this design.

•     Of note, 13 of 22 patients achieved a survival, measured from start of treatment with GaM, of greater than 12 months. One patient achieved a partial response and remains on treatment after more than 38 months.

The authors conclude that further investigation of the clinical efficacy of gallium maltolate in GBM is warranted, and that this will require a statistically powered, Phase 2 trial.

Regulatory status

Gallium maltolate holds Fast Track, two Orphan Drug and two Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA). These designations relate to the regulatory development pathway and do not constitute any determination of efficacy by the FDA.

Reopening of the Expanded Access Programme

In response to continued interest from patients and clinicians, Imaging Biometrics intends to reactivate its Expanded Access Programme (EAP) to enrol up to 20 additional patients. The EAP provides a route for eligible patients to access investigational gallium maltolate outside of a clinical trial. As an investigational agent, GaM has not been approved by any regulatory authority; its safety and efficacy have not been established. Decisions regarding suitability for the EAP are a matter for a patient's treating physician.

Comment

Trevor Brown, Chief Executive Officer of Imaging Biometrics Ltd, commented:

"We are encouraged that this trial has established a safe dosing regimen and a recommended Phase 2 dose for oral gallium maltolate. Although the study was not powered for efficacy, the results provide encouraging evidence of biological and clinical activity, including durable disease stabilization and prolonged survival in select patients. We are grateful to the patients and clinical investigators who made it possible. Glioblastoma remains an area of profound unmet need."

 

For further information, please contact:

 

Imaging Biometrics Limited

Trevor Brown / Brett Skelly / Michael Schmainda / John Richardson

Tel: 020 7469 0930

 

AlbR Capital Limited

Corporate Broker

Lucy Williams / Duncan Vasey

Tel: 020 7469 0930

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDGGDLLXGDGLI
NO INVESTMENT ADVICE

This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).

Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.

Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.

All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.

This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.

This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read